Hvilken er prisen på Novo Nordisk A/S (NOVO-B)

Prisen på Novo Nordisk A/S (NOVO-B) er $47.55

Hva er markedsverdien på Novo Nordisk A/S (NOVO-B)

Markedsverdien på Novo Nordisk A/S (NOVO-B) er $211.25B

Novo Nordisk A/S (NOVO-B) Inntekter

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

År	Inntekter	Endre
Ikke nok data for de angitte datoene.

År

Inntekter

Endre

Ikke nok data for de angitte datoene.

Selskap	Inntekter	Forskjell i inntekter	Land
Eli Lilly and Company LLY.US	$79.67B	64.10%	US
Johnson & Johnson JNJ.US	$97.93B	101.72%	US
AbbVie Inc. ABBV.US	$64.39B	32.62%	US
Roche Holding AG RO.SW	$77.52B	59.67%	CH
Merck & Co., Inc. MRK.US	$66.40B	36.77%	US

Selskap

Inntekter

Forskjell i inntekter

Land